Evotec, A.H.T. Syngas Technology, Deutsche Telekom: Stock Updates and Strategies
Evotec has sold its Toulouse production facility to Sandoz for approximately $350 million, refocusing on a capital-light model and core business profitability, while also receiving funding from the Gates Foundation to lower biotherapeutics development costs. A.H.T. Syngas Technology raised €2 million through a convertible bond to shift towards operating energy facilities in the syngas market, and Deutsche Telekom anticipates increasing dividends for 2025, supported by T-Mobile US growth and investments in fiber and 5G, despite high capital expenditures. Current stock prices are €5.82 for Evotec, €3.90 for AHT, and €27.16 for Deutsche Telekom.

Evotec sold a production facility in Toulouse to Sandoz for approximately $350 million, shifting to a capital-light model and focusing on profitable core businesses. Just - Evotec Biologics received funding from the Gates Foundation to reduce biotherapeutics development costs.
A.H.T. Syngas Technology raised €2 million through a convertible bond to transition from equipment manufacturing to operating energy facilities, aiming for stable revenues in the growing syngas market.
Deutsche Telekom expects to increase dividends for 2025, driven by T-Mobile US growth and investments in fiber and 5G networks, despite high capital expenditures impacting cash flow. Current stock prices are €5.82 for Evotec, €3.90 for AHT, and €27.16 for Deutsche Telekom.




Comments